Cargando…

Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Objective: The aim was to study the benefits and risks of anti-CD19 chimeric antigen receptor (CAR) T-cells in adults with B-cell lymphoma. Methods: From October 2015 to October 2021, we treated five patients with B-cell lymphoma, comprising two with mantle cell lymphoma, one case of Burkitt lymphom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Wenyujing, Chen, Weihong, Wan, Xiaochun, Luo, Changru, Du, Xin, Li, Xiaoqing, Chen, Qian, Gao, Ruiwen, Zhang, Xiaohan, Xie, Mei, Wang, Mingjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811184/ https://www.ncbi.nlm.nih.gov/pubmed/35126471 http://dx.doi.org/10.3389/fgene.2021.815679

Ejemplares similares

Mechanisms of failure of chimeric antigen receptor T-cell therapy
por: Li, Xiaoqing, et al.
Publicado: (2019)

Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
por: Alhabbab, Rowa Y.
Publicado: (2020)

Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma
por: Ping, Nana, et al.
Publicado: (2022)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
por: Tbakhi, Bushra, et al.
Publicado: (2022)

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
por: Atrash, Shebli, et al.
Publicado: (2021)

Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac Lymphoma
por: Lee, Dae Hyun, et al.
Publicado: (2022)

Efficacy and safety of chimeric antigen receptor-T cells in the treatment of B cell lymphoma: a systematic review and meta-analysis
por: Zheng, Xiao-Hong, et al.
Publicado: (2020)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

Biomarkers in individualized management of chimeric antigen receptor T cell therapy
por: Du, Mengyi, et al.
Publicado: (2020)

Case Report: Immune Microenvironment and Mutation Features in a Patient With Epstein–Barr Virus Positive Large B-Cell Lymphoma Secondary to Angioimmunoblastic T-Cell Lymphoma
por: Zhang, Fen, et al.
Publicado: (2022)

Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma
por: Snyder, Sophie, et al.
Publicado: (2021)

Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy
por: Yang, Yan, et al.
Publicado: (2020)

Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
por: Yin, Zixun, et al.
Publicado: (2021)

Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
por: Chu, Fuliang, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight
por: Land, Craig A., et al.
Publicado: (2020)

Case Report: Identification of Germline Chimerism in Monochorionic Dizygotic Twins
por: Chen, Juan, et al.
Publicado: (2021)

Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
por: Hao, Yuan-Yuan, et al.
Publicado: (2022)

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Wei, Yuang, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
por: Makita, Shinichi, et al.
Publicado: (2019)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2021)

Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2021)

Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2023)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma
por: Brammer, Jonathan E, et al.
Publicado: (2021)

Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
por: Potnis, Kunal C., et al.
Publicado: (2022)

Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients
por: Zhou, Yuxin, et al.
Publicado: (2023)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report
por: Chen, Hsin-Hui, et al.
Publicado: (2023)

Validation of next-generation sequencing-based chimerism testing for accurate detection and monitoring of engraftment in hematopoietic stem cell transplantation
por: Kakodkar, Pramath, et al.
Publicado: (2023)

Errors in mutagenesis and the benefit of cell-to-cell signalling in the evolution of stress-induced mutagenesis
por: Dellus-Gur, Eynat, et al.
Publicado: (2017)

Rewiring T-cell responses to soluble factors with chimeric antigen receptors
por: Chang, ZeNan L., et al.
Publicado: (2018)

Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
por: Li, Sujun, et al.
Publicado: (2019)

Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin Lymphoma
por: Ahrendsen, Jared T., et al.
Publicado: (2021)

Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma
por: Wen, Hairuo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jd559vjm3u2ba682m5h1ccbifu